pre-IPO PHARMA

COMPANY OVERVIEW

The mission of REVOLUTION Medicines is to discover and develop new drugs directed toward frontier oncology targets for cancer patients. Frontier targets include proteins that drive the growth and survival of cancer but carry atypical structural or regulatory features requiring unconventional drug discovery strategies. The company brings together deep talent in cancer biology and small molecule drug discovery supported by advanced chemical synthesis, computational and assay technologies to master these targets. Seasoned translational and development scientists help to fulfill the company’s commitment to precision oncology.


LOCATION

  • Redwood City, CA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.revolutionmedicines.com


    CAREER WEBSITE

    https://www.revolutionmedicines.com/careers


    SOCIAL MEDIA


    INVESTORS

    casdin-capital nextech-invest schroder-adveq the-column-group third-rock-ventures


    PRESS RELEASES


    Nov 4, 2019

    Revolution Medicines and Amgen Partner on Phase 1b Study to Evaluate Combination of RMC-4630 and AMG 510


    Oct 22, 2019

    Revolution Medicines to Present Preclinical Data on Novel Inhibitors of Oncogenic RAS(ON) Mutants at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics


    Sep 17, 2019

    REVOLUTION Medicines Announces Dosing of First Patient in RMC-4630-02, a Phase 1b/2 Trial Combining RMC-4630 with a MEK Inhibitor


    Jul 9, 2019

    REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers


    Jan 4, 2019

    REVOLUTION Medicines to Present at the J.P. Morgan Healthcare Conference on January 8, 2019


    For More Press Releases


    Google Analytics Alternative